Latest Conference

Alex Rinehart, PhD, explains how the development of a long-acting injectable offers a new preventive option for HIV.

Contagion® will be providing exclusive coverage on the conference, and so, keep your eyes peeled for session coverage and interviews with some of the key presenters.

David A. Schwartz, MD, MS Hyg, FCAP, explains how researchers from all over the world have come together to share their research on Zika virus.

Silvio Pitlik, MD, provides insight into the prevalence of Lyme disease in Israel.

Prof. Francisco Veas, PhD, chief security officer, Institut de Recherche pour le Développement, France, explains some of the issues faced by patients with Lyme disease living in Europe.

Hanneke Schuitemaker, PhD, explains the challenges faced when creating a vaccine for HIV.

Magda Opsomer, MD, shares the results of the Phase 3 EMERALD trial for darunavir.

Jessica Justman, MD, explains how decision makers can use the Population-based HIV Impact Assessment Project data.

Viviane Boaventura, MD, MsC, PhD, discusses ongoing research related to auditory complications due to congenital Zika syndrome.

Alan Gross, PharmD, shares the drawbacks of some of the current prediction tools used for pneumonia.

Joergen Richt, DVM, PhD, discusses which animal models are being used to study Zika virus.

Alex Rinehart, PhD, explains if cabotegravir interacts with any other medications.

Silvia Munoz-Price, MD, PhD, explains how the undefined role of a hospital epidemiologist can be problematic.

Jessica Justman, MD, reveals the latest results of the Population-based HIV Impact Assessment Project (2017).

Viviane Boaventura, MD, MsC, PhD, shares how past research has demonstrated that adults can experience Zika-associated hearing loss.

Silvio Pitlik, MD, visiting scientist, Weizmann Institute of Science, Israel, explains how the first Lyme disease patients were misdiagnosed.

Alan Gross, PharmD, shares how an early diagnosis of multidrug-resistant pneumonia can work towards improving patient outcomes.

Joergen Richt, DVM, PhD, discusses the transmission cycle of Zika virus.

Milena McLaughlin, PharmD, MSc, explains how officials test if a drug is counterfeit or active.

Meghan Jeffres, PharmD, shares what should be considered when considering the incorporation of penicillin skin testing into a health care facility.

Silvia Munoz-Price, MD, PhD, explains different elements that should be incorporated into training programs for hospital epidemiologists.

Alex Rinehart, PhD, identifies the target population for cabotegravir.

Jessica Justman, MD, shares why the Population-based HIV Impact Assessment Project is so important.

Alan Gross, PharmD, BCPS-AQID, shares how the Society of Infectious Diseases Pharmacists is working to improve antibiotic stewardship programs in long-term care facilities.

Joergen Richt, DVM, PhD, discusses animals that have proven susceptible to Zika virus replication after experimental infection.

Silvia Munoz-Price, MD, PhD, shares a few issues that hospital epidemiologists currently face.

Julian Hurdle, PhD, explains research focused on validating FabK as an essential enzyme to be used as a narrow-spectrum drug target against Clostridium difficile.

Jason Pogue, PharmD, BCPS-ID, explains the clinical significance of his research team’s findings regarding the use of ceftolozane-tazobactam to treat Pseudomonas infections.

Alex Rinehart, PhD, explains how cabotegravir is a gender-neutral pre-exposure prophylaxis medication.

Kenneth Mayer, MD, discusses some societal challenges that at-risk individuals face today that may keep them from taking pre-exposure prophylaxis.